Form 8-K Filing by Nexalin Technology, Inc.

This Form 8-K filing reports the departure of Carolyn Shelton from her position as Senior Vice President of Quality, Regulatory, and Clinical Affairs at Nexalin Technology, Inc. on August 28, 2026. In connection with her departure, Ms. Shelton and the Company have agreed to a separation package. This package includes one month of continued base salary, a $20,000 bonus for 2026, accelerated vesting of her unvested stock options, an extended period of up to two years to exercise her vested options, and continued health insurance premium subsidies until September 30, 2026. Ms. Shelton has agreed to a release of claims against the Company and standard confidentiality, non-disparagement, and cooperation clauses.